RPEP-13624 · 2025Models predicted SSTR expression with 70-83% accuracy using clinical parameters. Key predictors: tumor origin, oncological treatments, CK7. Associations: age, grade, disease extent, CEA, CA19-9, AFP. 65 patients, 392 lesions evaluated.
Sipka, Gábor; Farkas, István; Bakos, Annamária; Maráz, Anikó; Mikó, Zsófia Sára; Czékus, Tamás; Bukva, Mátyás; Urbán, Szabolcs; Pávics, László; Besenyi, Zsuzsanna ·
RPEP-13625 · 2025Incretins reduce neuroinflammation, protect BBB, and promote neuronal survival in TBI models. 70 million annual TBI cases (81% concussions). Already safe in diabetes patients. Ideal for rapid clinical trial evaluation.
Sipos, Samuel; Jerkic, Mirjana; Rotstein, Ori D; Schweizer, Tom A ·
RPEP-13626 · 2025Substance P increases chemokine release (not gene expression) from S. aureus-infected osteoclasts but not osteoblasts. NK-1R inhibition reduced disease severity in mouse osteomyelitis. Reduced leukocyte-attracting chemokines and osteoclast/neutrophil activity in vivo.
Sipprell, Sophie E; Krueger, Quinton A; Mills, Erin L; Marriott, Ian; Johnson, M Brittany ·
RPEP-13627 · 2025No increased risk: corticosteroids OR 0.93, treatment escalation OR 0.70, surgery OR 0.32. Weight loss: -7.33 kg (I²=0%), -6.67% body weight (I²=0%), BMI -2.48 (I²=0%). Flare incidence: 14%. 10,362 patients across 10 studies.
Siranart, Noppachai; Nakaphan, Pannathorn; Pajareya, Patavee; Laohasurayotin, Khamik ·
RPEP-13628 · 2025Semaglutide: -13.88% weight vs placebo -0.42% (difference -13.46%, p<0.0001). No change in clozapine/norclozapine levels. No change in PANSS psychosis scores. No treatment-related SAEs. Low constipation rates. 31 patients (15 sema, 16 placebo).
Siskind, Dan; Baker, Andrea; Arnautovska, Urska; Warren, Nicola; Russell, Anthony; DeMonte, Veronica; Halstead, Sean; Iyer, Ravi; Korman, Nicole; McKeon, Gemma; Medland, Sarah; Parker, Stephen; Stedman, Terry; Trott, Mike ·
RPEP-13629 · 2025vs Dulaglutide: Semaglutide MACE HR 0.85, mortality HR 0.81, stroke HR 0.82, revascularization HR 0.93. Liraglutide MACE HR 0.84, mortality HR 0.79. Exenatide: no significant differences. 81,854 patients at moderate CV risk.
Sklepinski, Stacey M; Deng, Yihong; Swarna, Kavya Sindu; Herrin, Jeph; Polley, Eric C; Neumiller, Joshua J; Galindo, Rodolfo J; Umpierrez, Guillermo E; Ross, Joseph S; Borah, Bijan J; Maron, Bradley A; Mickelson, Mindy M; McCoy, Rozalina G ·
RPEP-13630 · 2025No significant weight loss difference at 6 months (p=0.08) or 12 months (p=0.26) between age groups. Similar HbA1c (p=0.73), LDL (p=0.95), and BP changes. Fewer AEs in older adults (39% vs 61%). Lower AE-related discontinuation in older adults (0% vs 6%).
Smit, Haley; Hayen, Krista; Schartz, Kathryn; Metzger, Justin; Perry, Meghan ·
RPEP-13631 · 2025rMACE-3 HR 0.43 (p<0.001); rMACE-5 HR 0.55 (p<0.001); MACE-3 HR 0.58 (p<0.01); MACE-5 HR 0.65 (p<0.001). Reduced all-cause mortality, CV mortality, HF hospitalization, incident T2DM, and kidney events. 9,321 vs 18,642 matched.
Smolderen, Kim G; Mena-Hurtado, Carlos; Zhao, Zhenxiang; Michalak, Wojciech; Faurby, Mads; Smolarz, B Gabriel; Kosiborod, Mikhail N; Song, Jinlin; Chen, Yan; Boland, Joanna; Nanna, Michael G ·
RPEP-13632 · 2025Semaglutide: -19.2 lbs (-9.1%), HbA1c -0.54% (p=0.0001). Tirzepatide: -49.4 lbs (-21.4%), HbA1c -0.68%. Controls: no significant changes. 100 T1D patients over 1 year.
Snell-Bergeon, Janet K; Kaur, Gurleen; Renner, Drew; Akturk, Halis K; Beatson, Christie; Garg, Satish K ·
RPEP-13633 · 2025CAP (liver fat): -26.0 dB/m at 2 months (p significant). Liver stiffness: no significant change. BMI: 30.9→28.9 (p<0.001). HOMA-IR improved. MASLD criteria prevalence declined. 197 patients, 6-month follow-up.
So, Jae Eun; Jeong, Jaehong; Hong, Jung Pyo; Kim, Dong Yun; Lee, Jae Seung; Kim, Mi Na; Kim, Beom Kyung; Park, Jun Yong; Kim, Do Young; Lee, Hye Won; Kim, Seung Up ·
RPEP-13634 · 2025Exenatide: improved infarct size, salvage, cardiac function (mixed results in 2 larger trials). Liraglutide: improved salvage, infarct size, LVEF, stroke volume, reduced no-reflow. Both safe. No significant MACE reduction.
Soares, Leticia Alves; Paniagua, Cynthia; Nguyen, Julie; Kojic, Ajla; Sanfrey, Elena Rose; Reyome, Madison Emilee; Aguayo, Liliana; Sattler, Elisabeth Lilian Pia ·
RPEP-13635 · 20256MWD: +16.2m (p<0.001, I²=0%); SBP: -2.22 mmHg (p<0.01, I²=0%); CRP: ratio 0.59 (p<0.001, I²=51%); NT-proBNP: ratio 0.81 (p<0.001, I²=0%). 3 studies, 1,463 patients, 52 weeks.
Sobral, Milene Vitória Sampaio; Rodrigues, Livia Kneipp; Barbosa, Abner Mácola Pacheco; da Rocha, Naila Camila; Moulaz, Isac Ribeiro; Dos Santos, João Pedro Pereira; Oliveira, Bruno Henrique Couto; Moreira, João Lucas de Magalhães Leal; Pacagnelli, Francis Lopes; Guida, Camila Mota ·
RPEP-13636 · 2025Fat mass: -3.5% total, -2.0% visceral. Lean mass: +3.0% proportion. HbA1c: -1.2-1.8%. LDL: -0.16 mmol/L, total cholesterol: -0.48 mmol/L (unique among GLP-1RAs). Reduced hunger, increased satiety. Weight regain on discontinuation.
Sokary, Sara; Bawadi, Hiba ·
RPEP-13637 · 2025Weight loss: 5-20.9% (dose-dependent, 72 weeks). Fat mass primary driver. HbA1c: -20.4 to -28.2 mmol/mol. Reduced appetite, increased satiety. Improved cholesterol, LDL, triglycerides, HDL. GI AEs at higher doses; 4-10% discontinuation.
Sokary, Sara; Bawadi, Hiba ·
RPEP-13638 · 2025Hst5: 2 Cu(II) binding sites (Kd 0.2 µM and 14.8 µM). Hst8: 1 Cu(II) binding site (Kd 12.3 µM). Distinct antimicrobial profiles. Different copper binding mechanisms. Both tested against E. coli, S. aureus, C. albicans.
Sokołowska, Justyna; Słowik, Joanna; Zamłyńska, Katarzyna; Kutkowska, Jolanta; Lenartowicz, Paweł; Witkowska, Danuta ·
RPEP-13639 · 2025NPY and POMC: significantly lower in both UP and BP vs controls (p=0.001). NPY: lower in UP vs BP (NS). POMC: lower in BP vs UP (NS). No correlation with HAM-D, sleepiness, or eating scales.
Solak, Hatice; Gokcen, Onur ·
RPEP-13640 · 2025PNOC/NPY neurons (non-AgRP) identified in ARC. Lepr deletion in PNOC neurons → hyperphagia + obesity via NPY upregulation. Lepr restoration in PNOC neurons → substantial weight reduction. PNOC/NPY activation promotes feeding = all PNOCARC activation. NPY overexpression in PNOC → hyperphagia + obesity.
Solheim, Marie H; Stroganov, Sima; Chen, Weiyi; Subagia, P Sicilia; Bauder, Corinna A; Wnuk-Lipinski, Daria; Del Río-Martín, Almudena; Sotelo-Hitschfeld, Tamara; Beddows, Cait A; Klemm, Paul; Dodd, Garron T; Lundh, Sofia; Secher, Anna; Wunderlich, F Thomas; Steuernagel, Lukas; Brüning, Jens C ·
RPEP-13641 · 2025Cancer cells: minimal DEGs and immune-related changes after Tα1. Immune cells: significant transcriptional changes in all subsets. Greatest impact: activated CD8+ T cells. Tα1 directly affects immune cell proliferation and transcription.
Solmonese, Laura; Lofiego, Maria Fortunata; Fazio, Carolina; Marzani, Francesco; Piazzini, Francesca; Bello, Emma; Celesti, Fabrizio; Giacobini, Gianluca; Wang, Xiaohui; Maio, Michele; Coral, Sandra; Di Giacomo, Anna Maria; Covre, Alessia ·
RPEP-13642 · 2025Glycinated NPs: improved biocompatibility, RLX conjugation maintained. Preferential uptake by monocytes and T cells. Targeted delivery of anti-fibrotic peptide to relevant immune cells.
Somanader-Livera, Deidree V N; Wei, Chen; Wang, Chao; Li, Yifang; Ferens, Dorota; Salimova, Ekaterina; Selomulya, Cordelia; Hossain, Mohammed Akhter; Samuel, Chrishan S; Chakraborty, Amlan ·
RPEP-13643 · 2025Pipeline agents: retatrutide (triple), survodutide/mazdutide (GLP-1/glucagon), CagriSema/amycretin (amylin+GLP-1), maridebart cafraglutide (GIPR antagonist+GLP-1R agonist), danuglipron/orforglipron (oral small molecules). Multiple mechanisms under development.
Son, Jang Won; le Roux, Carel W; Blüher, Matthias; Nauck, Michael A; Lim, Soo ·
RPEP-13644 · 2025Unprovoked DVT after tirzepatide initiation. Negative hypercoagulability workup. Resolved with anticoagulation + drug discontinuation.
Sonavane, Kunal; Agrawal, Gautam; Agarwal, Bhawna; Parsi, Saketh; Ponnam, Hari Krishna Choudary; Shirsat, Pallavi ·
RPEP-13645 · 202535-year-old, no comorbidities. Tirzepatide for weight loss. Severe rhabdomyolysis. Muscle biopsy: necrotizing myopathy. No other cause identified. Resolved with drug cessation + IV fluids.
Sonavane, Kunal; Shirsat, Pallavi; Agrawal, Gautam; Agarwal, Bhawna ·
RPEP-13646 · 2025Semaglutide + NSCs: improved motor function. NSC survival: 3.258 vs 0.819 × 10⁻¹¹ photon flux (4x improvement). Reduced C3+ reactive astrocytes. RNA-seq: inflammatory factors in C3+ astrocytes hinder NSC differentiation. Semaglutide every other day for 4 weeks.
Song, Dan; Zou, Xiaoya; Ma, Di; Zhao, Yuying; Liu, Tingting; Shen, Bibiao; Cheng, Oumei ·
RPEP-13647 · 20254 novel CCK-stimulating peptides identified from oat. QGDVVALPA most potent. Mechanism: calcium-sensing receptor → Gq → intracellular Ca²⁺ → CaMKII → CCK secretion. OPH increased plasma CCK in mice.
Song, Hongdong; Xue, Lei; Fu, Qiuyun; Wang, Haiyan; Cao, Hongwei; Huang, Kai; Guan, Xiao ·
RPEP-13648 · 2025Both VIPER-STING drugamers enhanced DC maturation and CD8+ T cell responses. polySTING: more tumor-infiltrating CD8+ T cells. NPSTING: more LN antigen-presenting DCs. Both: efficacy in B16-OVA melanoma and MC38 colon cancer. Combination with anti-PD-1: tumor remission + immunity in subset.
Song, Kefan; Nguyen, Dinh Chuong; Wang, Yonghui; Jokonya, Simbarashe; Yazdani, Omeed; Sellers, Drew L; Stayton, Patrick S; Pun, Suzie H ·
RPEP-13649 · 2025SGLT2i vs incretins overall: HR 0.82. vs DPP-4i: HR 0.67. vs GLP-1RA: HR 0.93. Vascular dementia: HR 0.49. Alzheimer's: HR 0.68. Greater benefit in >65. Empagliflozin most protective.
Song, Kirim; Choi, Jiwon; Jeong, Dayeon; Shin, Dongyun; Ah, Young-Mi; Lee, Ki Young; Choi, Kyung Hee ·
RPEP-13650 · 2025GLP-1RA > SGLT2i for LVEF and MI/ACS reduction. DPP-4i > SGLT2i for LVEDV and LVESV. Dapagliflozin/empagliflozin: best for HF rehospitalization vs liraglutide. Albiglutide: lowest CV death vs exenatide. Dose-dependent effects documented.
Song, Ruirui; Liu, Fang; Shi, Xiaojing; Sun, Songtao; Chen, Jun; Gao, Hongmei ·
RPEP-13651 · 2025Max clinical score: 2.50 (EAE) vs 1.75 (EAE+liraglutide), p=0.005. Th1 cells: 11.95%→5.94% with liraglutide (p=0.025). Treg: no significant change. Body weight: no significant difference. n=10 per treatment group.
Song, Shuang; Li, Bin; Guo, Ruoyi; Zhou, Yi; Xue, Yumei; Guo, Li ·
RPEP-13652 · 2025YYLLVR: SBP -53.48 mmHg, DBP -37.57 mmHg. ACE2 expression increased 2-fold. Endothelial dysfunction markers improved (p<0.05 for multiple endpoints). Tested in SHR model.
Song, Wentian; Huang, Haoduo; Shen, Yue; Wu, Dan; Fang, Li; Liu, Xiaoting; Xu, Yu; Wang, Chongchong; Zhao, Fanrui; Liu, Chunlei; Min, Weihong ·
RPEP-13653 · 2025CGRP and SP upregulate MMPs and integrins in GBM. PACAP modulates cAMP-MAPK signaling. GBM spreads along trigeminal pathways on MRI. Aprepitant: GBM apoptosis. Gepants: reduce GBM invasion. Radiolabeled SP: focal alpha-therapy. Epidemiological: higher migraine antecedents in brain tumor patients.
Song, Xiaoli; Zhu, Qian; Zhang, Jieying; Yang, Jin; Zhang, Xinxin; Song, Qian ·
RPEP-13654 · 2025PLC coordinates MHC-I peptide loading (calreticulin, tapasin, ERp57, TAP). Tumor immune evasion through PLC component downregulation → reduced MHC-I. MHC-I loss → resistance to checkpoint inhibitors and adoptive T cell therapy. Restoring PLC function could overcome immune evasion.
Song, Zhidu; Tao, Ying; You, Jiaxin ·
RPEP-13655 · 2025Pharmacogenomic variants in GIP/GLP-1 receptor pathways influence tirzepatide response. Genetic susceptibility genes for T2DM and AS overlap with drug response pathways. Precision subtyping potential for individualized therapy.
Song, Zihang; Tang, Yifan; Peng, Mao; Han, Ruoyu; He, Pingping ·
RPEP-13656 · 2025Adropin: 0.61 ng/mL in T2DM (p significant vs controls). Correlations: HbA1c (r=-0.31), ACR (r=-0.59), CRP (r=-0.37), NT-proBNP (r=-0.44), eGFR (r=+0.31). AUC: DKD 0.946, DKD+CHF 0.965, T2DM+CHF 0.887.
Sonkar, Satyendra K; Agrawal, Madhusudan; Sonkar, Gyanendra K; Bhosale, Vivek; Gautam, Medhavi; Pradhan, Akshay; Kumar, Satish; Bhagchandani, Deepak; Singh, Abhishek ·
RPEP-13657 · 2025VIP microinfusion dose-dependently increased ATBF: 2.67→4.35→7.91 mL/100g/min (p<0.0001). 7/16 were non-responders to glucose ATBF. Non-responders: trend toward lower VIP response (NS). Oral glucose: no change in plasma VIP.
Sotorník, Richard; Ménard, Julie; Brassard, Pascal; Gagnon-Auger, Maude; Baillargeon, Jean-Patrice; Ardilouze, Jean-Luc ·
RPEP-13658 · 2025Cyclic peptides: structural stability, enhanced bioavailability, target specificity. Nanocarrier types: liposomes, niosomes, nanosponges, nanopolymers. Benefits: targeted delivery, controlled release, drug resistance overcome. Sources: plant, marine, microbial.
Souresh, Vedhapriya; Srikayalsamyukktha, M; Harini, M; Saravanan, Yudhesh; Saravanakumar, Rupachandra ·
RPEP-13659 · 2025Obesity mechanisms in pancreatic disease: gallstone formation, hypertriglyceridemia, lipotoxicity, intrapancreatic fat, inflammation, adipokine imbalance, oncogenic signaling. GLP-1RAs and tirzepatide: promising weight loss interventions reducing disease burden. Paradoxical protective effect in CP.
Souto, Mariana; Cúrdia Gonçalves, Tiago; Cotter, José ·
RPEP-13660 · 2025Fibrosis regression top SUCRA: pegozafermin (79.92), cilofexor+firsocostat (71.38). MASH resolution top SUCRA: pegozafermin (91.75), survodutide (90.87), tirzepatide (84.70). 8 agents better than placebo for fibrosis; 12 for resolution. 29 RCTs, 9,324 patients.
Souza, Matheus; Al-Sharif, Lubna; Antunes, Vanio L J; Huang, Daniel Q; Loomba, Rohit ·
RPEP-13661 · 2025Sensory nerves release CGRP and SP → modulate macrophages and immune cells. Macrophage IL-1β, IL-6, TNF-α → sensitize nociceptors. CCL2 → engages neuronal receptors for excitability. Sympathetic signaling → immune modulation. Synovial remodeling: nerve sprouting + immune infiltration.
Sow, Tammie Tao Min; Hasegawa, Tetsuo ·
RPEP-13662 · 2025Acute dipyrone reduced CGRP-induced allodynia in both sexes. Chronic dipyrone (30 days): latent sensitization in females only (revealed by bright light). No effect on paw threshold, locomotion, or plasma CGRP. Sex-dependent vulnerability.
Spagnol, Fernanddo José; Zortea, Julia Maria; Gomes, Larissa Cieslinsky; da Luz, Fernanda Mariano Ribeiro; Baggio, Darciane Favero; Lejeune, Vanessa Bordenowsky Pereira; Ferreira, Luiz Eduardo Nunes; Kopruszinski, Caroline Machado; Chichorro, Juliana Geremias ·
RPEP-13663 · 2025Semaglutide directly activated GLP-1R on myotubes. Improved mitochondrial respiration in insulin-resistant cells. Enhanced insulin-stimulated glucose uptake. Effects independent of weight loss (cell culture model).
Spry, Emmalie R; Travis, Kipton B; Ragland, Kayla J; Klein, Alexa J; Zimmerman, John M; Vaughan, Roger A ·
RPEP-13664 · 2025GLP-1RAs achieved clinically significant preoperative weight loss in obese hernia patients. Enabled surgical candidacy for previously ineligible patients. Potential to reduce obesity-related surgical complications.
Spurzem, Graham J; Broderick, Ryan C; Ruiz-Cota, Patricia; Rocha, Amanda; Reyes, Edgardo; Fontaine-Nicola, Andres; Altolaguirre, Agustina; Hollandsworth, Hannah M; Sandler, Bryan J; Grunvald, Eduardo; Jacobsen, Garth R ·
RPEP-13665 · 2025Average TBWL: 12.2%. Hyper-responders (>15%): 33.8%. Non-responders (<5%): 17.8%. Female sex → hyper-response OR 1.92 (p=0.048). No association: diabetes, BMI, age, sedentary status, anxiety, depression.
Squire, Peter; Naude, James; Zentner, Ali; Bittman, Jesse; Khan, Nadia ·
RPEP-13666 · 2025All three neuropeptides (CGRP, VIP, PACAP-38) significantly elevated in migraine vs controls (p<0.001). MA > MO for all three. MA trends: higher attack frequency (p=0.06), HIT-6 (p=0.08). 296 participants.
Sreevani, N; Ramesh, B; Maheshkumar, K; Thanalakshmi, J ·
RPEP-13667 · 2025Kisspeptin-10: normalized body weight, glucose, energy intake. Increased GIP+ and GLP-1+ gut cells. Restored villi length, crypt depth. Restored insulin area and glucagon radius. Increased beta-cell proliferation. Enhanced FSH and LH. 21-day treatment, 25 nmol/kg IP.
Sridhar, Ananyaa; Khan, Dawood; Muthukumar, Rithiga; Sampathkumar, Swetha; Irwin, Nigel; Flatt, Peter R; Moffett, R Charlotte ·
RPEP-13668 · 2025GLP-1RAs: improved menstrual frequency, weight, FAI, free testosterone, androstenedione, SHBG, triglycerides, insulin resistance, glucose. SGLT2is: improved FAI, total testosterone, WHR, AGF, HOMA-IR (outperformed GLP-1 for FAI, testosterone, LDL, HOMA-IR). Combination > monotherapy for weight, fat, triglycerides, glucose. 27 RCTs, 1,642 patients.
Sridharan, Kannan; Sivaramakrishnan, Gowri ·
RPEP-13669 · 2025Anakinra: RR 0.29 (95% CI 0.09-0.91). Empagliflozin: RR 0.29. Dasiglucagon: effective rescue. Pasireotide + acarbose: 100% prevention in single-arm studies. Liraglutide, verapamil, semaglutide: variable in case reports. 13 comparative + 5 single-arm + 15 case reports.
Sridharan, Kannan; Sivaramakrishnan, Gowri ·
RPEP-13670 · 2025GLP-1RAs interact with dopaminergic, GABAergic, and opioidergic addiction pathways. Preclinical + early clinical evidence for reducing alcohol and substance use. Already approved for T2DM, obesity, and OSA—enabling rapid evaluation for ASUDs.
Srinivasan, Nirupam M; Farokhnia, Mehdi; Farinelli, Lisa A; Ferrulli, Anna; Leggio, Lorenzo ·
RPEP-13671 · 2025Dual Gcg/GLP-1 agonists: GLP-1 reduces appetite + glucagon increases energy expenditure. Benefits across obesity, T2DM, MASLD/MASH, CVD. Survodutide: significant weight loss + liver fat reduction. Mazdutide: weight + glycemic benefits. Glucagon component adds thermogenesis and hepatic fat clearance.
Stachteas, Panagiotis; Nasoufidou, Athina; Karakasis, Paschalis; Koiliari, Markella; Karagiannidis, Efstratios; Koufakis, Theocharis; Fragakis, Nikolaos; Patoulias, Dimitrios ·
RPEP-13672 · 2025MQ232: low acute/chronic toxicity. Strong kidney biodistribution. Pure aquaretic effect (water only, no electrolytes). Improved kidney histology in PKD mouse model. Derived from snake toxin with disulfide-bond reticulation.
Stanajic-Petrovic, Goran; Keck, Mathilde; Barbe, Peggy; Urman, Apolline; Correia, Evelyne; Isnard, Pierre; Duong Van Huyen, Jean-Paul; Chmeis, Khawla; Diarra, Sékou Siramakan; Palea, Stefano; Theodoro, Frederic; Nguyen, Anvi-Laëtitia; Castelli, Florence; Pruvost, Alain; Zhao, Wenchao; Mendre, Christiane; Mouillac, Bernard; Bienaimé, Frank; Robin, Philippe; Kessler, Pascal; Llorens-Cortes, Catherine; Servent, Denis; Nozach, Hervé; Maillère, Bernard; Guo, Dong; Truillet, Charles; Gilles, Nicolas ·
RPEP-13673 · 2025GLP-1 considerations for plastic surgery: delayed gastric emptying (anesthesia risk), wound healing effects, facial volume loss requiring restoration, body contouring timing, medication hold protocols. Covers all major GLP-1 drugs.
Stanton, Eloise W; Manasyan, Artur; Banerjee, Rakhi; Hong, Kurt; Koesters, Emma; Daar, David A ·